Analysis of neuroendocrine clones in NSCLCs using an immuno-guided laser-capture microdissection-based approach

por Baldelli, Elisa, Mandarano, Martina, Bellezza, Guido, Petricoin, Emanuel F., Pierobon, Mariaelena
Publicado 2022

Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology

por Bianconi, Fortunato, Baldelli, Elisa, Luovini, Vienna, Petricoin, Emanuel F., Crinò, Lucio, Valigi, Paolo
Publicado 2015

Erratum to: ‘Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology’

por Bianconi, Fortunato, Baldelli, Elisa, Ludovini, Vienna, Petricoin, Emanuel F., Crinò, Lucio, Valigi, Paolo
Publicado 2016

Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis

por Le Roux, Özgün, Pershing, Nicole LK, Kaltenbrun, Erin, Newman, Nicole J, Everitt, Jeffrey I, Baldelli, Elisa, Pierobon, Mariaelena, Petricoin, Emanuel F, Counter, Christopher M
Publicado 2022

The impact of ultraviolet- and infrared-based laser microdissection technology on phosphoprotein detection in the laser microdissection-reverse phase protein array workflow

por Hunt, Allison L., Pierobon, Mariaelena, Baldelli, Elisa, Oliver, Julie, Mitchell, Dave, Gist, Glenn, Bateman, Nicholas W., Larry Maxwell, G., Petricoin, Emanuel F., Conrads, Thomas P.
Publicado 2020

Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study

por Ludovini, Vienna, Chiari, Rita, Tomassoni, Lorenzo, Antonini, Chiara, Baldelli, Elisa, Baglivo, Sara, Siggillino, Annamaria, Tofanetti, Francesca Romana, Bellezza, Guido, Hodge, K. Alex, Petricoin, Emanuel, Pierobon, Mariaelena, Crinò, Lucio, Bianconi, Fortunato
Publicado 2017

Heterogeneous Off-Target Effects of Ultra-Low Dose Dimethyl Sulfoxide (DMSO) on Targetable Signaling Events in Lung Cancer In Vitro Models

por Baldelli, Elisa, Subramanian, Mahalakshmi, Alsubaie, Abduljalil M., Oldaker, Guy, Emelianenko, Maria, El Gazzah, Emna, Baglivo, Sara, Hodge, Kimberley A., Bianconi, Fortunato, Ludovini, Vienna, Crino’, Lucio, Petricoin, Emanuel F., Pierobon, Mariaelena
Publicado 2021

Integrated multi-omics analyses on patient-derived CRC organoids highlight altered molecular pathways in colorectal cancer progression involving PTEN

por Codrich, Marta, Dalla, Emiliano, Mio, Catia, Antoniali, Giulia, Malfatti, Matilde Clarissa, Marzinotto, Stefania, Pierobon, Mariaelena, Baldelli, Elisa, Di Loreto, Carla, Damante, Giuseppe, Terrosu, Giovanni, Pucillo, Carlo Ennio Michele, Tell, Gianluca
Publicado 2021

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors

por Baldelli, Elisa, Bellezza, Guido, Haura, Eric B., Crinó, Lucio, Cress, W. Douglas, Deng, Jianghong, Ludovini, Vienna, Sidoni, Angelo, Schabath, Matthew B., Puma, Francesco, Vannucci, Jacopo, Siggillino, Annamaria, Liotta, Lance A., Petricoin, Emanuel F., Pierobon, Mariaelena
Publicado 2015

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas

por Baldelli, Elisa, El Gazzah, Emna, Moran, John Conor, Hodge, Kimberley A., Manojlovic, Zarko, Bassiouni, Rania, Carpten, John D., Ludovini, Vienna, Baglivo, Sara, Crinò, Lucio, Bianconi, Fortunato, Dong, Ting, Loffredo, Jeremy, Petricoin, Emanuel F., Pierobon, Mariaelena
Publicado 2021

Kinase-driven metabolic signalling as a predictor of response to carboplatin–paclitaxel adjuvant treatment in advanced ovarian cancers

por Sereni, Maria Isabella, Baldelli, Elisa, Gambara, Guido, Ravaggi, Antonella, Hodge, K Alex, Alberts, David S, Guillen-Rodriguez, Jose M, Dong, Ting, Memo, Maurizio, Odicino, Franco, Angioli, Roberto, Liotta, Lance A, Pecorelli, Sergio L, Petricoin, Emanuel F, Pierobon, Mariaelena
Publicado 2017

AKT/mTOR signaling modulates resistance to endocrine therapy and CDK4/6 inhibition in metastatic breast cancers

por Abu-Khalaf, Maysa M., Alex Hodge, K., Hatzis, Christos, Baldelli, Elisa, El Gazzah, Emna, Valdes, Frances, Sikov, William M., Mita, Monica M., Denduluri, Neelima, Murphy, Rita, Zelterman, Daniel, Liotta, Lance, Dunetz, Bryant, Dunetz, Rick, Petricoin, Emanuel F., Pierobon, Mariaelena
Publicado 2023

The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancer

por Diehl, J. Nathaniel, Klomp, Jennifer E., Snare, Kayla R., Hibshman, Priya S., Blake, Devon R., Kaiser, Zane D., Gilbert, Thomas S.K., Baldelli, Elisa, Pierobon, Mariaelena, Papke, Björn, Yang, Runying, Hodge, Richard G., Rashid, Naim U., Petricoin, Emanuel F., Herring, Laura E., Graves, Lee M., Cox, Adrienne D., Der, Channing J.
Publicado 2021

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine

por Baldelli, Elisa, Hodge, K Alex, Bellezza, Guido, Shah, Neil J, Gambara, Guido, Sidoni, Angelo, Mandarano, Martina, Ruhunusiri, Chamodya, Dunetz, Bryant, Abu-Khalaf, Maysa, Wulfkuhle, Julia, Gallagher, Rosa I, Liotta, Lance, de Bono, Johann, Mehra, Niven, Riisnaes, Ruth, Ravaggi, Antonella, Odicino, Franco, Sereni, Maria Isabella, Blackburn, Matthew, Zupa, Angela, Improta, Giuseppina, Demsko, Perry, Crino', Lucio, Ludovini, Vienna, Giaccone, Giuseppe, Petricoin, Emanuel F, Pierobon, Mariaelena
Publicado 2021

Multi‐omic molecular profiling guide’s efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial

por Pierobon, Mariaelena, Robert, Nicholas J., Northfelt, Donald W., Jahanzeb, Mohammad, Wong, Shukmei, Hodge, Kimberly A., Baldelli, Elisa, Aldrich, Jessica, Craig, David W., Liotta, Lance A., Avramovic, Sanja, Wojtusiak, Janusz, Alemi, Farrokh, Wulfkuhle, Julia D., Bellos, Angela, Gallagher, Rosa I., Arguello, David, Conrad, Amber, Kemkes, Ariane, Loesch, David M., Vocila, Linda, Dunetz, Bryant, Carpten, John D., Petricoin, Emanuel F., Anthony, Stephen P.
Publicado 2021

CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment

por Klomp, Jennifer E., Lee, Ye S., Goodwin, Craig M., Papke, Björn, Klomp, Jeff A., Waters, Andrew M., Stalnecker, Clint A., DeLiberty, Jonathan M., Drizyte-Miller, Kristina, Yang, Runying, Diehl, J. Nathaniel, Yin, Hongwei H., Pierobon, Mariaelena, Baldelli, Elisa, Ryan, Meagan B., Li, Siqi, Peterson, Jackson, Smith, Amber R., Neal, James T., McCormick, Aaron K., Kuo, Calvin J., Counter, Christopher M., Petricoin, Emanuel F., Cox, Adrienne D., Bryant, Kirsten L., Der, Channing J.
Publicado 2021